gefitinib has been researched along with Minimal Disease, Residual in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, M; Harada, H; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Miyawaki, E; Miyawaki, T; Mori, K; Murakami, H; Naito, T; Nishioka, N; Omori, S; Ono, A; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Funakoshi, Y; Maeda, H; Takeuchi, Y | 1 |
| Aokage, K; Hishida, T; Nagai, K; Tsuboi, M; Yoshida, J | 1 |
| Akiyama, H; Hishida, T; Horinouchi, H; Kondo, H; Mitsudomi, T; Nagai, K; Nagayasu, T; Tsuboi, M; Yokoi, K | 1 |
| Hashimoto, K; Hayashi, Y; Horinouchi, H; Izumi, Y; Kohno, M; Nomori, H; Ohtsuka, T | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Bashar, AH; Funai, K; Kazui, T; Mori, H; Sugimura, H; Suzuki, K; Takamochi, K | 1 |
1 review(s) available for gefitinib and Minimal Disease, Residual
| Article | Year |
|---|---|
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
6 other study(ies) available for gefitinib and Minimal Disease, Residual
| Article | Year |
|---|---|
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Topics: Acrylamides; Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Failure | 2021 |
Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Empyema, Pleural; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Node Excision; Mutation; Neoadjuvant Therapy; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pneumonectomy; Quinazolines | 2016 |
Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm, Residual; Quinazolines; Salvage Therapy | 2012 |
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Quinazolines | 2007 |